{"id":"https://openalex.org/W3009824331","doi":"https://doi.org/10.7573/dic.2019-11-4","title":"Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection","display_name":"Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection","publication_year":2020,"publication_date":"2020-03-03","ids":{"openalex":"https://openalex.org/W3009824331","doi":"https://doi.org/10.7573/dic.2019-11-4","mag":"3009824331","pmid":"https://pubmed.ncbi.nlm.nih.gov/32180823","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7055513"},"language":"en","primary_location":{"id":"doi:10.7573/dic.2019-11-4","doi":"https://doi.org/10.7573/dic.2019-11-4","is_oa":true,"landing_page_url":"https://doi.org/10.7573/dic.2019-11-4","pdf_url":"https://www.drugsincontext.com/wp-content/uploads/2020/02/dic.2019-11-4-COI.pdf","source":{"id":"https://openalex.org/S2764578562","display_name":"Drugs in Context","issn_l":"1740-4398","issn":["1740-4398","1745-1981"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310311745","host_organization_name":"BioExcel Publishing Ltd","host_organization_lineage":["https://openalex.org/P4310311745"],"host_organization_lineage_names":["BioExcel Publishing Ltd"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in Context","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.drugsincontext.com/wp-content/uploads/2020/02/dic.2019-11-4-COI.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024034549","display_name":"Hanh Thi Pham","orcid":"https://orcid.org/0000-0001-7818-0994","observed_orcids":["https://orcid.org/0000-0001-7818-0994"]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Hanh Thi Pham","raw_affiliation_strings":["Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada","McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010251930","display_name":"Meng A Xiao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Meng A Xiao","raw_affiliation_strings":["Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada","McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038983433","display_name":"Miguel Alfonso V. Principe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Miguel AV Principe","raw_affiliation_strings":["Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada","institution_ids":["https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048076117","display_name":"Alexander Wong","orcid":"https://orcid.org/0009-0009-9781-5479","observed_orcids":["https://orcid.org/0009-0009-9781-5479"]},"institutions":[{"id":"https://openalex.org/I194028371","display_name":"University of Regina","ror":"https://ror.org/03dzc0485","country_code":"CA","type":"education","lineage":["https://openalex.org/I194028371"]},{"id":"https://openalex.org/I32625721","display_name":"University of Saskatchewan","ror":"https://ror.org/010x8gc63","country_code":"CA","type":"education","lineage":["https://openalex.org/I32625721"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Alexander Wong","raw_affiliation_strings":["Department of Medicine, University of Saskatchewan, Regina, SK, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Saskatchewan, Regina, SK, Canada","institution_ids":["https://openalex.org/I194028371","https://openalex.org/I32625721"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045766366","display_name":"Thibault M\u00e9spl\u00e8de","orcid":"https://orcid.org/0000-0003-0515-9128","observed_orcids":["https://orcid.org/0000-0003-0515-9128"]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Thibault Mespl\u00e8de","raw_affiliation_strings":["Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada","McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5045766366"],"corresponding_institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669","https://openalex.org/I5023651"],"apc_list":{"value":1550,"currency":"GBP","value_usd":1901},"apc_paid":{"value":1550,"currency":"GBP","value_usd":1901},"fwci":0.2362,"has_fulltext":true,"cited_by_count":30,"citation_normalized_percentile":{"value":0.43384184,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"9","issue":null,"first_page":"1","last_page":"11"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/doravirine","display_name":"doravirine","score":1.0},{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.9419999718666077},{"id":"https://openalex.org/keywords/hiv-1-infection","display_name":"HIV-1 infection","score":0.984000027179718},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.800000011920929},{"id":"https://openalex.org/keywords/islatravir","display_name":"islatravir","score":0.9490000009536743},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.9409999847412109},{"id":"https://openalex.org/keywords/clinical-efficacy","display_name":"clinical efficacy","score":0.49399998784065247}],"concepts":[{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.717003345489502},{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.6843488812446594},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6459560990333557},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5966929793357849},{"id":"https://openalex.org/C2909970146","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Nucleoside Reverse Transcriptase Inhibitor","level":5,"score":0.5546374917030334},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.5472192764282227},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.5283653736114502},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.45331430435180664},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41730791330337524},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38899311423301697},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.35844409465789795},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.25742530822753906},{"id":"https://openalex.org/C2776452011","wikidata":"https://www.wikidata.org/wiki/Q311463","display_name":"Sida","level":4,"score":0.23934638500213623},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18778637051582336},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.1726219356060028},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.16473180055618286},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14622312784194946},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.1395106315612793},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.05555340647697449},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.0}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.7573/dic.2019-11-4","doi":"https://doi.org/10.7573/dic.2019-11-4","is_oa":true,"landing_page_url":"https://doi.org/10.7573/dic.2019-11-4","pdf_url":"https://www.drugsincontext.com/wp-content/uploads/2020/02/dic.2019-11-4-COI.pdf","source":{"id":"https://openalex.org/S2764578562","display_name":"Drugs in Context","issn_l":"1740-4398","issn":["1740-4398","1745-1981"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310311745","host_organization_name":"BioExcel Publishing Ltd","host_organization_lineage":["https://openalex.org/P4310311745"],"host_organization_lineage_names":["BioExcel Publishing Ltd"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in Context","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7055513","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7055513","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs Context","raw_type":"Text"},{"id":"pmid:32180823","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32180823","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in context","raw_type":"Journal Article"},{"id":"pmh:oai:pure.eur.nl:openaire/a6c36e21-f629-4d2a-ae40-cb389fd22560","doi":null,"is_oa":true,"landing_page_url":"https://pure.eur.nl/en/publications/a6c36e21-f629-4d2a-ae40-cb389fd22560","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pham, H T, Xiao, M A, Principe, M A V, Wong, A & Mespl\u00e8de, T 2020, 'Pharmaceutical, clinical, and resistance information on doravirine, a novel nonnucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection', Drugs in Context, vol. 9, 4. https://doi.org/10.7573/DIC.2019-11-4","raw_type":"info:eu-repo/semantics/review"},{"id":"pmh:eur:oai:pure.eur.nl:publications/a6c36e21-f629-4d2a-ae40-cb389fd22560","doi":null,"is_oa":true,"landing_page_url":"https://pure.eur.nl/en/publications/a6c36e21-f629-4d2a-ae40-cb389fd22560","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Drugs in Context, 9:4. BioExcel Publishing Ltd.","raw_type":"info:eu-repo/semantics/other"},{"id":"pmh:oai:doaj.org/article:1b9f754af1734f00bd6bbcf2772961ce","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/1b9f754af1734f00bd6bbcf2772961ce","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Drugs in Context, Vol 9, Pp 1-11 (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.7573/dic.2019-11-4","doi":"https://doi.org/10.7573/dic.2019-11-4","is_oa":true,"landing_page_url":"https://doi.org/10.7573/dic.2019-11-4","pdf_url":"https://www.drugsincontext.com/wp-content/uploads/2020/02/dic.2019-11-4-COI.pdf","source":{"id":"https://openalex.org/S2764578562","display_name":"Drugs in Context","issn_l":"1740-4398","issn":["1740-4398","1745-1981"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310311745","host_organization_name":"BioExcel Publishing Ltd","host_organization_lineage":["https://openalex.org/P4310311745"],"host_organization_lineage_names":["BioExcel Publishing Ltd"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in Context","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.979200005531311}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3009824331.pdf","grobid_xml":"https://content.openalex.org/works/W3009824331.grobid-xml"},"referenced_works_count":30,"referenced_works":["https://openalex.org/W1988831468","https://openalex.org/W2004013930","https://openalex.org/W2073157159","https://openalex.org/W2077754502","https://openalex.org/W2115295975","https://openalex.org/W2117681036","https://openalex.org/W2129228641","https://openalex.org/W2149148148","https://openalex.org/W2151768713","https://openalex.org/W2160877552","https://openalex.org/W2256825639","https://openalex.org/W2327696366","https://openalex.org/W2344166414","https://openalex.org/W2416139320","https://openalex.org/W2601741382","https://openalex.org/W2753610576","https://openalex.org/W2789289526","https://openalex.org/W2792742326","https://openalex.org/W2803560531","https://openalex.org/W2889157553","https://openalex.org/W2897642221","https://openalex.org/W2897671112","https://openalex.org/W2912401376","https://openalex.org/W2913150510","https://openalex.org/W2938502016","https://openalex.org/W2965906673","https://openalex.org/W2969281750","https://openalex.org/W2976414912","https://openalex.org/W2982613471","https://openalex.org/W2985077821"],"related_works":["https://openalex.org/W3084799445","https://openalex.org/W3006945212","https://openalex.org/W4380290416","https://openalex.org/W3088022191","https://openalex.org/W4319444417","https://openalex.org/W2905212625","https://openalex.org/W4415479045","https://openalex.org/W3210104300","https://openalex.org/W2256825639","https://openalex.org/W2969281750"],"abstract_inverted_index":{"As":[0],"part":[1],"of":[2,32,44,63,74,101,117],"a":[3,42,104,111],"combined":[4],"antiretroviral":[5,159],"regimen,":[6],"doravirine":[7,102,120,178,194],"is":[8,84,143,161],"safe":[9],"and":[10,19,47,128,174],"effective":[11],"at":[12,76],"suppressing":[13],"viral":[14],"replication":[15],"in":[16,114,126,138,153,195],"both":[17],"treatment-naive":[18,58],"treatment-experienced":[20,168],"adults":[21],"living":[22],"with":[23,88,179,197],"human":[24],"immunodeficiency":[25],"virus":[26],"(HIV)-1":[27],"who":[28],"have":[29,67],"no":[30,51],"history":[31],"drug":[33,65,183],"resistance":[34,52,66,156],"against":[35,123,157],"doravirine.In":[36],"virologically":[37],"suppressed":[38],"individuals":[39],"switching":[40],"to":[41,134,163],"combination":[43,196],"doravirine,":[45],"lamivudine,":[46],"tenofovir":[48],"disoproxil":[49],"fumarate,":[50],"was":[53],"found":[54,152],"after":[55],"48":[56],"weeks.In":[57],"individuals,":[59],"rare":[60],"cases":[61],"(<2%)":[62],"emergent":[64],"been":[68],"reported,":[69],"often":[70],"involving":[71],"the":[72,99,115,136,146],"development":[73],"substitutions":[75],"position":[77],"V106.From":[78],"these":[79],"few":[80],"clinical":[81,130,154,175,191],"cases,":[82],"it":[83],"inferred":[85],"that":[86],"crossresistance":[87],"other":[89],"non-nucleoside":[90],"reverse":[91],"transcriptase":[92],"inhibitors":[93],"(NNRTIs)":[94],"should":[95,107],"be":[96,108,135,164],"limited.In":[97],"contrast,":[98],"use":[100],"as":[103,140],"second":[105],"NNRTI":[106,150],"evaluated":[109],"on":[110,182],"case-by-case":[112],"basis":[113],"presence":[116],"pre-existing":[118],"resistance.Importantly,":[119],"remains":[121],"active":[122],"K103N":[124,142],"viruses":[125],"vitro,":[127],"limited":[129],"evidence":[131],"suggests":[132],"this":[133],"case":[137],"patients":[139],"well.Since":[141],"by":[144],"far":[145],"most":[147],"prevalent":[148],"(<70%)":[149],"substitution":[151],"practice,":[155],"doravirine-based":[158],"therapies":[160],"expected":[162],"rare,":[165],"even":[166],"for":[167],"individuals.This":[169],"review":[170],"summarizes":[171],"chemical,":[172],"pharmacological,":[173],"information":[176],"about":[177],"an":[180,188],"emphasis":[181],"resistance.The":[184],"efficacy":[185],"results":[186],"from":[187],"early":[189],"phase":[190],"trial":[192],"evaluating":[193],"islatravir":[198],"are":[199],"also":[200],"provided.":[201]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":3},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2020-03-13T00:00:00"}